(Hypertension. 2000;36:355.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From Christchurch Cardioendocrine Research Group, Christchurch School of Medicine (C.J.P., T.G.Y., E.A.E.), University of Otago, and Christchurch Hospital, Christchurch, New Zealand, and the Departments of Pharmacology and Internal Medicine, University of Virginia Health Sciences Center (M.L.J.), Charlottesville, Va.
Correspondence to Tim G. Yandle, PhD, Endolab, 2nd Floor Riverside, Private Bag 4710, Riccarton Ave, Christchurch Hospital, Christchurch 1, New Zealand. E-mail tim.yandle{at}chmeds.ac.nz
AbstractCardiac natriuretic peptides, especially amino terminal proBrain Natriuretic Peptide (NT-proBNP), are emerging as powerful circulating markers of cardiac function. However, the in vivo secretion and elimination (t1/2) of these peptides during acute volume overload have not been studied. We present the first report of the secretion and elimination of cardiac natriuretic peptides, based on deconvolution analysis of endogenous ovine plasma levels measured by specific radioimmunoassay. Four normal, conscious sheep underwent rapid right ventricular pacing (225 bpm) for 1 hour to stimulate acute cardiac natriuretic peptide release. Plasma samples and right atrial pressure measurements were taken at regular intervals 30 minutes before, during, and 4 hours after pacing. Baseline right atrial pressure significantly increased (P=0.02) during the 1 hour of pacing in association with a prompt increase in plasma BNP (P=0.03), atrial natriuretic peptide (P=0.01), and NT-proBNP (P=0.02). Deconvolution analysis showed that the t1/2 of NT-proBNP (69.6±10.8 minutes) was 15-fold longer than BNP (4.8±1.0 minutes). Despite sustained increases in atrial pressure, cardiac secretion of natriuretic peptides (particularly atrial natriuretic peptide) fell during the pacing period, suggesting a finite source of peptide for secretion. Size-exclusion high-performance liquid chromatography revealed NT-proBNP to be a single immunoreactive peak, whereas BNP comprised at least 2 immunoreactive forms. These findings, especially the prompt secretion of BNP and the prolonged t1/2 of NT-proBNP, clarify the metabolism of BNP forms and help to explain the diagnostic value of NT-proBNP measurement as a sensitive marker of ventricular function.
Key Words: heart failure natriuretic peptides myocytes metabolism
This article has been cited by other articles:
![]() |
S. C. Palmer, T. G. Yandle, M. G. Nicholls, C. M. Frampton, and A. M. Richards Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma Eur J Heart Fail, September 1, 2009; 11(9): 832 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Dhar, G S Pressman, S Subramanian, S Kaul, S Gollamudi, E J Bloom, and V M Figueredo Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence Postgrad. Med. J., June 1, 2009; 85(1004): 299 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C H J Michielsen, J. A Bakker, R. R J V. Kimmenade, Y. M Pinto, and M. P V. Dieijen-Visser The diagnostic value of serum and urinary NT-proBNP for heart failure Ann Clin Biochem, July 1, 2008; 45(4): 389 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Roberts, P. M. Srivastava, N. Macmillan, D. L. Hare, S. Ratnaike, K. Sikaris, and F. L. Ierino B-type Natriuretic Peptides Strongly Predict Mortality in Patients Who Are Treated with Long-Term Dialysis Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1057 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Due-Andersen, U. Pedersen-Bjergaard, T. Hoi-Hansen, N. V. Olsen, C. Kistorp, J. Faber, F. Boomsma, and B. Thorsteinsson NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity J Appl Physiol, April 1, 2008; 104(4): 1080 - 1085. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Paniagua, D. Amato, S. Mujais, E. Vonesh, A. Ramos, R. Correa-Rotter, and W. H. Horl Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 407 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Damgaard, J. P. Goetze, P. Norsk, and N. Gadsboll Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy individuals and patients with compensated heart failure Eur. Heart J., November 2, 2007; 28(22): 2726 - 2731. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Ronkainen, O. Vuolteenaho, and P. Tavi Calcium-Calmodulin Kinase II Is the Common Factor in Calcium-Dependent Cardiac Expression and Secretion of A- and B-Type Natriuretic Peptides Endocrinology, June 1, 2007; 148(6): 2815 - 2820. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kwan, S. R. Isakson, J. Beede, P. Clopton, A. S. Maisel, and R. L. Fitzgerald Short-Term Serial Sampling of Natriuretic Peptides in Patients Presenting With Chest Pain J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1186 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Konstam Natriuretic Peptides and Cardiovascular Events: More Than a Stretch JAMA, January 10, 2007; 297(2): 212 - 214. [Full Text] [PDF] |
||||
![]() |
M. Schou, F. Gustafsson, P. H. Nielsen, L. H. Madsen, A. Kjaer, and P. R. Hildebrandt Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state Eur J Heart Fail, January 1, 2007; 9(1): 68 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y.-M. Wang, C. W.-K. Lam, C.-M. Yu, M. Wang, I. H.-S. Chan, Y. Zhang, S.-F. Lui, and J. E. Sanderson N-Terminal Pro-Brain Natriuretic Peptide: An Independent Risk Predictor of Cardiovascular Congestion, Mortality, and Adverse Cardiovascular Outcomes in Chronic Peritoneal Dialysis Patients J. Am. Soc. Nephrol., January 1, 2007; 18(1): 321 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muscari, A. Berzigotti, G. Bianchi, C. Giannoni, A. Ligabue, D. Magalotti, D. Sbano, A. Zacchini, and M. Zoli Non-cardiac determinants of NT-proBNP levels in the elderly: Relevance of haematocrit and hepatic steatosis Eur J Heart Fail, August 1, 2006; 8(5): 468 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al. Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data Clin. Chem., August 1, 2006; 52(8): 1528 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Giuliani, F. Rieunier, C. Larue, J.-F. Delagneau, C. Granier, B. Pau, M. Ferriere, M. Saussine, J.-P. Cristol, A.-M. Dupuy, et al. Assay for Measurement of Intact B-Type Natriuretic Peptide Prohormone in Blood Clin. Chem., June 1, 2006; 52(6): 1054 - 1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. O. Neverdal, C. W. Knudsen, T. Husebye, O. A. Vengen, J. Pepper, M. Lie, and T. Tonnessen The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis -- one year follow-up Eur J Heart Fail, May 1, 2006; 8(3): 257 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.A. Gould, J. D'Agostino, H.G. Schneider, and D.M. Kaye Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure Eur J Heart Fail, May 1, 2006; 8(3): 263 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Damgaard, P. Norsk, F. Gustafsson, J. K. Kanters, N. J. Christensen, P. Bie, L. Friberg, and N. Gadsboll Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2006; 290(5): R1294 - R1301. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Costello-Boerrigter, G. Boerrigter, M. M. Redfield, R. J. Rodeheffer, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, D. M. Heublein, and J. C. Burnett Jr Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community: Determinants and Detection of Left Ventricular Dysfunction J. Am. Coll. Cardiol., January 17, 2006; 47(2): 345 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schou, M. K. Dalsgaard, O. Clemmesen, E. A. Dawson, C. C. Yoshiga, H. B. Nielsen, F. Gustafsson, P. R. Hildebrandt, and N. H. Secher Kidneys extract BNP and NT-proBNP in healthy young men J Appl Physiol, November 1, 2005; 99(5): 1676 - 1680. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Miller, K. A. Hartman, M. F. Burritt, D. D. Borgeson, J. C. Burnett Jr, and A. S. Jaffe Biomarker Responses during and after Treatment with Nesiritide Infusion in Patients with Decompensated Chronic Heart Failure Clin. Chem., March 1, 2005; 51(3): 569 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schnabel, H. J. Rupprecht, K. J. Lackner, E. Lubos, C. Bickel, J. Meyer, T. Munzel, F. Cambien, L. Tiret, S. Blankenberg, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study Eur. Heart J., February 1, 2005; 26(3): 241 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Goetze, J. F. Rehfeld, R. Videbaek, L. Friis-Hansen, and J. Kastrup B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts Eur J Heart Fail, January 1, 2005; 7(1): 69 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Goetze Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited Clin. Chem., September 1, 2004; 50(9): 1503 - 1510. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hall Essential biochemistry and physiology of (NT-pro)BNP Eur J Heart Fail, March 15, 2004; 6(3): 257 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gegenhuber, T. Mueller, F. Firlinger, K. Lenz, W. Poelz, and M. Haltmayer Time Course of B-Type Natriuretic Peptide (BNP) and N-Terminal ProBNP Changes in Patients with Decompensated Heart Failure Clin. Chem., February 1, 2004; 50(2): 454 - 456. [Full Text] [PDF] |
||||
![]() |
J. G. Lainchbury, E. Campbell, C. M. Frampton, T. G. Yandle, M. G. Nicholls, and A. M. Richards Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath J. Am. Coll. Cardiol., August 20, 2003; 42(4): 728 - 735. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Alehagen, G. Lindstedt, H. Eriksson, and U. Dahlstrom Utility of the Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma for the Evaluation of Cardiac Dysfunction in Elderly Patients in Primary Health Care Clin. Chem., August 1, 2003; 49(8): 1337 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |